Loading…
Employees: 4,738
Size Neuca (NEU.WA) is a Poland Health Care company (Medical Distributors) with a market value of $817M, the 45th largest of 83 Poland companies the cockpit tracks. Shares closed at PLN 695.00 on 6 Nov 2026.
Performance Over six months the shares fell 0.9%, against -2.9% for the median peer and +14.3% for the Poland market (cap-weighted) — 11th highest of 21 in its peer set.
Growth Revenue grew 8.4% over the last twelve months (peer median +3.3%); the operating margin is 2.1% (peer median 1.8%).
Valuation It trades at 15.3× forward earnings against a peer median of 14.2× (5th most expensive of 10).
Price implies For today's price to make sense, revenue must grow about 5% a year for seven years (Req g). Recent delivered growth is +8%, so the hurdle is -3 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 2.3 points above its cost of capital (9.2% WACC).
Next results Next results expected around 19 Nov 2026 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | PLN 14.1B | PLN 13.6B | PLN 12.6B | PLN 11.8B | PLN 11.2B |
| Revenue growth | — | +8% | +7% | +5% | — |
| Gross profit | PLN 1.64B | PLN 1.56B | PLN 1.44B | PLN 1.31B | PLN 1.13B |
| EBITDA | PLN 431M | PLN 360M | PLN 363M | PLN 366M | PLN 330M |
| Net income | PLN 197M | PLN 156M | PLN 154M | PLN 146M | PLN 137M |
| Free cash flow | PLN 219M | PLN 372M | -PLN 88.1M | PLN 123M | PLN 220M |
| Capital expenditure | PLN 130M | PLN 125M | PLN 92.9M | PLN 94.2M | PLN 81.4M |
| Total debt | PLN 797M | PLN 853M | PLN 742M | PLN 663M | PLN 562M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | NEU.WA | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -1.4% | +1.0% | 8th lowest of 21 |
| 6-month return | -0.9% | -2.9% | 11th highest of 21 |
| Distance from 52-week high | -18.9% | -19.0% | 11th highest of 21 |
| Revenue growth (TTM) | +8.4% | +3.3% | 6th highest of 21 |
| Operating margin | 2.1% | 1.8% | 11th highest of 21 |
| Forward P/E | 15.3× | 14.2× | 5th most expensive of 10 |
| Growth the price implies (Req g, 7 yrs) | 5.0% | -0.4% | 6th most demanding of 17 |
| Growth delivered (Del g) | +8.1% | +5.4% | 4th highest of 17 |
| Hurdle (Req g minus delivered) | -3.0 pp | -6.2 pp | 8th most demanding of 17 |
| ROIC minus cost of capital | +2.3 pp | +0.2 pp | 5th highest of 21 |
| Net debt / EBITDA | 1.5× | -1.5× | 4th most indebted of 11 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Neuca NEU.WA | Poland | $817M | -1% | +8% | 2% | 15.3× | 5.0% | +8.1% |
| Entero Healthcare Solutions ENTERO.NS | India | $875M | +50% | +32% | 4% | 46.5× | 21.8% | +29.9% |
| Shanghai Haohai Biological Technology 6826.HK | Hong Kong | $926M | -27% | -5% | -2% | 7.9× | 17.2% | +12.4% |
| Guangxi LiuYao 603368.SS | China | $994M | +2% | +2% | 5% | 9.9× | -9.5% | +6.0% |
| Arjo ARJO-B.ST | Sweden | $1.02B | +48% | 0% | 8% | 21.3× | -1.3% | +3.9% |
| DocMorris DOCM.SW | Switzerland | $1.02B | +136% | +11% | -8% | n/a | n/a | n/a |
| Nanjing Pharmaceutical 600713.SS | China | $1.03B | +1% | +3% | 2% | n/a | n/a | n/a |
| Shanghai New World 600628.SS | China | $623M | -11% | -2% | 6% | n/a | 0.3% | +1.0% |
| AS ONE 7476.T | Japan | $1.08B | +15% | +10% | 12% | 18.2× | -1.0% | +6.3% |
| Shinva Medical Instrument 600587.SS | China | $1.16B | -7% | +6% | 5% | 14.2× | -5.9% | +1.2% |
| GKHT Medical Technology 301370.SZ | China | $569M | -22% | -11% | 1% | n/a | 14.4% | +7.5% |
| Shanghai C and D INNOSTIC Medical Technology 301584.SZ | China | $1.20B | -28% | +8% | 3% | n/a | -1.3% | +17.9% |
| Arata 2733.T | Japan | $552M | -7% | +3% | 1% | 11.9× | -7.1% | +3.8% |
| Shanghai Lily & Beauty Cosmetics 605136.SS | China | $517M | -21% | +10% | 0% | n/a | 12.2% | -18.1% |
| Thalys Medical Technology 603716.SS | China | $501M | -29% | -41% | -17% | n/a | n/a | n/a |
| Ship Healthcare 3360.T | Japan | $1.34B | +4% | +7% | 3% | 13.8× | -14.7% | +7.6% |
| Shenzhen Neptunus Bioengineering 000078.SZ | China | $475M | -60% | -22% | -1% | n/a | 59.0% | -7.8% |
| Vital KSK 3151.T | Japan | $428M | +7% | +2% | 1% | n/a | 0.4% | +2.6% |
| Toho 8129.T | Japan | $1.60B | -14% | +4% | 1% | 21.6× | -7.4% | +5.1% |
| Redcare Pharmacy RDC.DE | Germany | $1.63B | +52% | +19% | 0% | n/a | n/a | n/a |
| Excelsior Medical 4104.TW | Taiwan | $409M | +1% | +6% | 8% | n/a | 2.9% | +5.7% |